PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Colonic neoplasm

Drugs in development · updated 30 October 2026

Colonic neoplasm: drugs in development

As of 30 October 2026 there are 142 active clinical trials (recruiting or ongoing, phases I–III) on 157 drugs for colonic neoplasm. 78 are experimental, that is not yet approved in the United States.

142Active trials
78Experimental drugs
8Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
QL1706III3NCT06686576
SerplulimabHLX10, Hetronifly®III3NCT07877597
INCA33890III2NCT07284849
CalderasibIII1NCT06997497
NuvastaticIII1NCT07669519
Nuvastatic 300III1NCT07669454
PF-08634404III1NCT07222800
RC148II–III1NCT07462143
SintilimabSinitilimab, SindilimabII4NCT07840677
BalstilimabBalstililmab, BalstilmabI–II3NCT05627635
BotensilimabI–II3NCT05627635
TuvonralimabII3NCT06949111
ChidamideTucidinostat, HBI-8000II2NCT06709885
ElironrasibRMC-6291I–II2NCT06128551
FianlimabREGN3767II2NCT07058012
IparomlimabiparomilimabII2NCT06949111
RMC-6236I–II2NCT05379985
0% IP-001 for InjectionI–II1NCT05688280
AdavosertibAZD1775II1NCT02465060
ARV-806I–II1NCT07023731
BHB810I–II1NCT07529808
BLU-924I–II1NCT07629960
BMS-986253HuMax-IL8II1NCT03026140
CadonilimabAK104, CandonilimabII1NCT07003022
CamrelizumabCarrelizumab, CarilizumabII1NCT06215677
ERK1I–II1NCT04616183
EvorpaceptALX148I–II1NCT05868226
FexagratinibAZD4547II1NCT02465060
FuquinitinibII1NCT06255379
GSK4418959I–II1NCT06710847
GSK5460025I–II1NCT07213609
HLX07I–II1NCT07358585
HLX43I–II1NCT07358585
IpatasertibII1NCT02465060
IvonescimabAK112II1NCT06790212
MDX2001I–II1NCT06239194
NBT-NM108II1NCT05296681
OleclumabMEDI9447I–II1NCT04068610
PorustobartHBM4003II1NCT07808151
RaltitrexedII1NCT06652412

Sorted by most advanced phase and number of active trials. Showing 40 of 78 drugs.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
OxaliplatinOxaliplatine, OxaliplainII–III23NCT07462143
CetuximabErbituxII–III19NCT05710406
Bevacizumabavastin, MVASIIII18NCT07284849
CapecitabineXeloda, Capectitabine TabletsII–III15NCT07462143
LeucovorinFolinic acid, l-leucovorinII–III13NCT04068103
Fluorouracil5-Fluorouracil, AdrucilII–III11NCT04068103
IrinotecanOnivyde, CPT-11III11NCT04607421
NivolumabOpdivo, ONO-4538III9NCT06490536
EncorafenibBraftovi®II–III8NCT05710406
TislelizumabTisleizumab, TiselizumabIII6NCT07132008
DostarlimabTSR-042, Jemperli®III4NCT05855200
IpilimumabYERVOY, ipililumab IVIII4NCT06490536
AdagrasibMRTX849, Krazati®III3NCT04793958
AtezolizumabTecentriq, MPDL3280AIII3NCT02912559
PertuzumabPerjeta, Poherdy®III3NCT03803553

Sorted by most advanced phase and number of active trials. Showing 15 of 79 drugs.

All 157 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D003110 “Colonic Neoplasms”.

ItalianoFrançaisDeutsch